secwatch.observer — SEC 8-K summary
======================================

Issuer:     VYNE Therapeutics Inc. (VYNE)
CIK:        0001566044
Form:       8-K
Filed at:   2024-12-23T23:59:59+00:00
Accession:  0001104659-24-131064
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

VYNE reports positive Phase 1a MAD data for VYN202; no AE, robust biomarker activity
--------------------------------------------------------------------------------

- VYN202 showed favorable safety with no drug-related AEs, including no thrombocytopenia or neutropenia.
- PK supports once-daily dosing; dose-dependent exposure reached steady-state after 7 days.
- Increased target engagement biomarker HEXIM-1; inhibited Th17, Th1/myeloid, Th1/Tc inflammatory biomarkers.
- No drug-drug interaction when co-administered with methotrexate, a common treatment for immune conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1566044/000110465924131064/0001104659-24-131064-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1566044/000110465924131064/tm2431817d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-131064

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer